A phase I/II trial of pinometostat plus standard chemotherapy (NCT03724084)in pediatric and adult patients with newly diagnosed MLL-rearranged AML is currently ongoing [55]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.